The article emphasizes the significance of biomarker testing in the treatment of advanced gastroesophageal cancer. Dr. Yelena Janjigian highlights the importance of routine testing for biomarkers to enhance patient outcomes. Key biomarkers such as MSI, HER2, and PD-L1 are discussed, along with the impact of targeted therapies on survival rates. The need for continued advancements in patient selection through biomarker testing is underscored.
To Another Language
from source content
www.medscape.com
Key Insights Distilled From
by M. Alexander... at www.medscape.com 01-22-2024
https://www.medscape.com/viewarticle/case-biomarker-testing-gastroesophageal-cancer-2024a10001koDeeper Inquiries